Exact Sciences Corp. (EXAS) Company Profile & Statistics

Exact Sciences Corp.
EXAS
(Nasdaq - US)
Closed
71.50
+0.37 (+0.52%)
in:usd•As of: Nov 05, 2024 15:59 UTC -5
After Market:50.25-21.25 (-29.72%)
Open
71.00
High
72.79
Low
70.22

About Exact Sciences Corp.

CEO

Kevin T. Conroy

Headquarters

5505 endeavor lane

madison, wi 53719, united states

Auditor

PricewaterhouseCoopers LLP

Employees

6,600

Share Holders

179

Website

www.exactsciences.com

Industry

medical specialties

Sector

health technology

Company Overview

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.

Exact Sciences Corp. Statistics

Valuation Measures

Market Capitalization ²	13.21B
Enterprise Value	15.25B
Enterprise Value/EBITDA (ttm)	476.14
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	4.04
Price to Sales (ttm)	4.94
Price to Cash (ytd)	4.10K

Profitability

Gross Margin (ttm)	73.19%
Operating Margin (ttm)	-6.00%
Profit Margin (ttm)	-6.78%
Return on Equity (ttm)	-4.97%
Return on Invested Capital (ttm)	-3.30%
Return on Assets (ttm)	-2.41%

Income Statement

Revenue (ttm)	2.61B
Revenue Per Share (ttm)	14.14
Gross Profit (ttm)	1.91B
EBITDA (ttm)³	32.02M
Net Income Avi to Common (ttm)	-175.01M
Diluted EPS (ttm)	-0.96

Share Statistics

Beta (5Y Monthly)	1.27
52-Week Change	9.66%
S&P500 52-Week Change	32.45%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	184.77M
Dividend Yield	0.00%
Float ⁴	182.26M
% Held by Insiders	1.36%
% Held by Institutions	88.82%

Balance Sheet

Total Cash (mrq)	946.78M
Total Cash Per Share (mrq)	5.12
Total Debt (mrq)	2.57B
Total Debt/Equity (mrq)	80.41%
Current Ratio (mrq)	2.17%
Quick Ratio (mrq)	1.98%
Book Value Per Share (mrq)	17.29

Cash Flow

Operating Cash Flow Per Share (ytd)	0.13
Free Cash Flow (ytd)	-48.76M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Exact Sciences Corp.

Trade With A Regulated Broker